ClinicalTrials.gg
CompletedNCT04799964Updated Sep 19, 2024

Efficacy and Safety of the Flow Diverter (Tonbridge) for Endovascular Treatment of Intracranial Aneurysms

An interventional study of Flow Diverter (Tonbridge) and Tubridge (MicroPort) in Intracranial Aneurysm, sponsored by Zhuhai Tonbridge Medical Tech. Co., Ltd.. Completed at 13 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Zhuhai Tonbridge Medical Tech. Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 100 studies in Intracranial Aneurysm with a site in China — 38 open to participants now, 42 under way, 1 of them phase 3. Intracranial Aneurysm · China.

Enrollment
26th of 49
187 · median 188
Started
2021
with 7 others
No phase
37 of 100
13 open now
Registered
36th of 100
by date

Among the 100 studies in Intracranial Aneurysm with a site in China, this one is the 26th largest by enrollment of the 49 interventional ones that give a count, is one of 8 that started in 2021, is one of 37 with no phase, and was the 36th registered.

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

38 of the 100 studies in Intracranial Aneurysm with a site in China are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies in Intracranial Aneurysm with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of the Flow Diverter (Tonbridge) for endovascular treatment of intracranial aneurysms.

Read the detailed description

This is a prospective, multi-center, randomized, open, positive-controlled, non-inferiority trial. This clinical trial is conducted at more than 5 centers in China. Eligible patients are randomized into experimental group using Flow Diverter (Tonbridge) or control group using Tubridge (MicroPort) in a 1:1 ratio. The primary objective of this study is to verify the complete occlusion rate of aneurysms at 12 months of Flow Diverter (Tonbridge) is non-inferior to Tubridge, for treatment of intracranial aneurysms, and evaluate the effectiveness and safety of the Flow Diverter (Tonbridge).

03

Conditions studied

  • Intracranial Aneurysm

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 80 years, any gender;
  • Unruptured intracranial aneurysms locate in the internal carotid artery (ICA) or vertebral artery (VA) with a neck ≥ 4 mm and a maximal diameter ≥ 10 mm, which diagnosed by DSA;
  • The target aneurysm with a parent vessel diameter of 2.0-6.5 mm;
  • Subject or guardian is able to understand the purpose of study, shows sufficient compliance with the study protocol and provides a signed form.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed as multiple aneurysms which cannot be covered by a single stent or with cerebrovascular malformations;
  • Subarachnoid hemorrhage of the target aneurysm within 30 days pre-procedure;
  • Modified Rankin Scale (mRS) score > 2 in pre-procedure;
  • (PLT) \< 60×10\^9/L or known platelet dysfunction or (INR) > 1.5;
  • Heart, lung, liver and renal failure or other severe diseases (such as brain tumor, systemic infection, disseminated intravascular coagulation, myocardial infarction within 12 months before enrollment, history of severe psychosis);
  • The lesion which is not appropriate for flow diverter delivery and deployment judged by investigators (severe stenosis of parent artery, severe tortuosity of parent artery, stent failing to reach the lesion, etc.);
  • Major surgery within 30 days before enrollment, or intending to receive surgery within 180 days after enrollment;
  • Allergic history of anesthetics and contrast agents, or for dual antiplatelet or/and anticoagulant therapy;
  • Allergic History of metals such as nickel-titanium alloy;
  • \< 12 months;
  • Pregnant or breastfeeding women;
  • Subject has participated in other drug or medical device clinical trials within 1 month before signing ;
  • Other conditions judged by the investigators as unsuitable for enrollment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
187 participants (actual)

Study arms

  • Experimental
    Flow Diverter (Tonbridge)

    Treatment with Flow Diverter (Tonbridge)

    Device: Flow Diverter (Tonbridge)

  • Active comparator
    Tubridge (MicroPort)

    Treatment with Tubridge (MicroPort)

    Device: Tubridge (MicroPort)

Interventions

  • DeviceFlow Diverter (Tonbridge)

    The device is a self-expanding vascular stent system, which consists of a stent and a delivery system. The stent is made of platinum core nickel-titanium alloy material. The delivery system is composed of a delivery guide wire and an introducer sheath. The stent and the delivery guide wire are pre-installed in the introducer sheath.

  • DeviceTubridge (MicroPort)

    Tubridge consists of a stent system and a microcatheter system. The stent system consists of a stent and a conveyor, the stent is self-expanding as well.

06

What researchers measure

Primary outcomes

  1. Complete occlusion rate of aneurysms at 12 months

    Complete occlusion is defined as no contrast agent in the aneurysm (Raymond-Roy class I) which is diagnosed by cerebrovascular DSA at 12 months post-procedure.

    Time frame: 360±45 days post-procedure

Secondary outcomes

  1. Immediate procedural success rate

    Intraoperative cerebrovascular DSA is performed to determine whether the investigational device positions exactly and covers the aneurysm neck effectively.

    Time frame: intra-procedure

  2. Complete occlusion rate of aneurysms at 6 months

    Complete occlusion is defined as no contrast agent in the aneurysm (Raymond-Roy class I) which is diagnosed by MRA/CTA at 6 months post-procedure.

    Time frame: 180±30 days post-procedure

  3. Subtotal occlusion rate

    Subtotal occlusion is defined as contrast agents in the aneurysm sac less than 10% which is diagnosed by DSA at 12 months post-procedure.

    Time frame: 360±45 days post-procedure

  4. Incidence of technical complications

    Technical complications include but not limited to: stent incomplete opening, stent migration, stent herniation into the aneurysm sac, in-stent thrombosis, operation injury, etc.

    Time frame: intra-procedure

  5. Incidence of stroke

    Stroke includes hemorrhagic stroke and symptomatic ischemic stroke.

    Time frame: within 360±45 days

  6. Incidence of parent artery stenosis ( > 50%) in target area at 360 days and incidence of parent artery occlusion in target area at 360 days

    Parent artery stenosis in target area is defined as stenosis degree \> 50%. Using postoperative cerebrovascular DSA at 360 days is performed to determine.

    Time frame: 360±45 days post-procedure

  7. Incidence of adverse events and incidence of serious adverse events

    "Incidence of adverse events" is the proportion of subjects with adverse events using the investigational device or the comparator; "Incidence of serious adverse events" is the proportion of subjects with serious adverse events using the investigational device or the comparator.

    Time frame: within 360±45 days

  8. Mortality rate

    Deaths due to any cause are calculated.

    Time frame: within 360±45 days

  9. Operation satisfaction rate

    The 5-point Likert scale is used to evaluate the operation satisfaction from three aspects: push performance, retracting performance and release performance. "Operation satisfaction rate" is defined as the proportion of investigational devices or comparators with Likert score ≥ 12 points.

    Time frame: intra-procedure

  10. Incidence of device deficiency

    Device deficiency is the unreasonable risk that may endanger human health and life safety in the normal use of medical devices during clinical trials, such as labeling errors, quality problems, malfunctions, etc.

    Time frame: within 360±45 days

07

Study locations

13 sites
  • The First Affiliated Hospital of USTC
    Hefei, Anhui, China
  • Nanfang Hospital Southern Medical University
    Guangzhou, Guangdong, China
  • Zhujiang Hospital of Southern Medical University
    Guangzhou, Guangdong, China
  • Nanyang Central Hospital
    Nanyang, Henan, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • Yichang Central People's Hospital
    Yichang, Hubei, China
  • Hunan Provincial People's Hospital
    Changsha, Hunan, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Zhejiang Hospital
    Hangzhou, Zhejiang, China
  • Changhai Hospital of Shanghai
    Shanghai, China
  • Huashan Hospital Fudan University
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Sep 2023, 25 months.

Of 47 industry-sponsored interventional studies with no phase under Intracranial Aneurysm, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 49. This study's 25 months is below that.

Counting every sponsor, half of 106 studies reached it within 39 months; a quarter within 22 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2021
First posted
Mar 16, 2021
StartActual
Aug 12, 2021
Primary completionActual
Sep 22, 2023
CompletionActual
Sep 22, 2023
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04799964
Lead sponsor
Zhuhai Tonbridge Medical Tech. Co., Ltd.
Responsible party
Sponsor
First posted
Mar 16, 2021
Start date
Aug 12, 2021
Primary completion
Sep 22, 2023
Completion
Sep 22, 2023
Last update
Sep 19, 2024

Study contacts

Jianmin Liu
principal investigator · Changhai Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion